Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib

被引：0
|
作者：
Smith, Jarrod T. [1 ]
Puri, Sonam [2 ]
Akerley, Wallace [2 ,3 ]
机构：
[1] Univ Utah, Dept Internal Med, Salt Lake City, UT USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Huntsman Canc Inst, Med, Rm 2169 2000 Circle Hope, Salt Lake City, UT 84112 USA
来源：
CLINICAL LUNG CANCER | 2023年 / 24卷 / 04期
关键词：
EGFR mutation; Lung adenocarcinoma; Non-small-cell lung cancer; Tyrosine kinase inhibitor; treatment; L833V; H835L;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 361
页数：2
相关论文
共 20 条
  • [1] A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review
    Yang, Xian
    Yao, Yang
    Zhu, Qing
    HELIYON, 2022, 8 (12)
  • [2] Clinical Response to Osimertinib in a Non-Small-Cell Lung Cancer Patient With EGFR L833V/H835L Mutations: A Case Report
    Al-Nusair, Jowan
    Bodiwala, Reesha
    Nwanwene, Kemnasom
    Abdallah, Mahmoud
    Alshal, Mohamed
    Pacioles, Toni
    JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2024, 12
  • [3] Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
    Long, Xiang
    Qin, Tian
    Lin, Junhong
    ONCOTARGETS AND THERAPY, 2020, 13 : 10689 - U67
  • [4] The effectiveness of sequential afatinib and furmonertinib in an advanced lung adenocarcinoma with rare compound EGFR mutation (L833V/H835L)
    Pan, Yanqing
    Yan, Lingxin
    Gu, Yongyao
    Wang, Shaoxi
    Li, Huiling
    Yu, Pengli
    Chen, Quanfang
    ANTI-CANCER DRUGS, 2025, 36 (04) : 355 - 358
  • [5] Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review
    Li, Linlin
    Huang, Siyuan
    Qin, Liying
    Yan, Ningning
    Shen, Shujing
    Li, Xingya
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] 罕见EGFR L833V/H835L复合突变的肺腺癌患者1例及文献回顾
    缪永恩
    汪瑜堃
    李萍
    谈敏
    文婷婷
    王昌惠
    谢栓栓
    中国肺癌杂志, 2023, (10) : 795 - 800
  • [7] The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Yuan, Ling-Yan
    Liu, Ke
    Wang, Zhan
    Qin, Wen-Xing
    Zang, Yuan-Sheng
    ONCOTARGETS AND THERAPY, 2018, 11 : 4739 - 4745
  • [8] Successful intercalating multimodal treatment strategy in a patient with advanced adenocarcinoma of the lung harboring the uncommon complex EGFR mutation L833V/H835L
    Frille, A.
    Saendig, I
    Wirtz, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 92 - 92
  • [9] A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib
    Frega, Stefano
    Conte, PierFranco
    Fassan, Matteo
    Polo, Valentina
    Pasello, Giulia
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) : E63 - E64
  • [10] Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V/H835L) lung adenocarcinoma patient: a case report
    Luo, Zhilin
    Luo, Chengwen
    Zhou, Runquan
    Xiao, Yajie
    Wang, Tianhu
    ANTI-CANCER DRUGS, 2023, 34 (08) : 939 - 941
12